J Edit pioglitazone – כדאי לבדוק… FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer[12-12-2016] As a result of an updated review, the U.S. Food and Drug Administration (FDA) has concluded that use of the type 2 diabetes medicine pioglitazone (Actos, Actoplus Met, Actoplus Met XR, Duetact, Oseni) עוד... 0הגיבושתפוהועתק ללוחדווחו הוסיפו תגובה תוכן שליחה 3 תגובות pioglitazone – כדאי לבדוק… תוכן<p>FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer<br ></p> <div style="width:350px"><a target="_blank" rel="nofollow" href="http://www.fda.gov/Drugs/DrugSafety/ucm519616.htm">FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer[12-12-2016] As a result of an updated review, the U.S. Food and Drug Administration (FDA) has concluded that use of the type 2 diabetes medicine pioglitazone (Actos, Actoplus Met, Actoplus Met XR, Duetact, Oseni) may be linked to an increased risk of bladder cancer.</a></div> <div style="clear:both"></div> <p></p> מחיקה עריכת הפוסט ביטול שמירה